HealthCare Global EnterprisesNSE:HCG -2.25%79 EBITDA Margin % is 16.42% as of Mar. 2026, which is 4% below its 10-year median of 17.11. GuruFocus rates NSE:HCG with a GF Score™ of 79/100 and a GF Value™ of ₹576.14 (Fairly Valued). The stock has 2 warning signs investors should review. Among 668 Healthcare Providers & Services companies, HealthCare Global Enterprises ranks better than 69.01% on this metric.
HealthCare Global Enterprises (NSE:HCG) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
HealthCare Global Enterprises EBITDA Margin % Related Terms
HealthCare Global Enterprises EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HealthCare Global Enterprises EBITDA Margin % Chart
NSE:HCG vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, HealthCare Global Enterprises's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HealthCare Global Enterprises EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, HealthCare Global Enterprises's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where HealthCare Global Enterprises's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HealthCare Global Enterprises (NSE:HCG) has a EBITDA Margin % of 16.42% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on HealthCare Global Enterprises and its competitors. This is near median its historical median of 17.11. Over the past decade, HealthCare Global Enterprises' EBITDA Margin % has ranged from 4.07 to 24.06. According to the industry distribution chart, HealthCare Global Enterprises ranks #207 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 31%.
Is HealthCare Global Enterprises' EBITDA Margin % too high?
HealthCare Global Enterprises' current EBITDA Margin % of 16.42% is near median its 10-year median of 17.11. Over the past 10 years, this metric has ranged from a low of 4.07 to a high of 24.06. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. HealthCare Global Enterprises' value of 16.42% is 60.8% above this industry median. Based on the distribution chart, HealthCare Global Enterprises ranks #207 out of 668 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, HealthCare Global Enterprises has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HealthCare Global Enterprises' EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, HealthCare Global Enterprises ranks #207 out of 668 companies for EBITDA Margin %. This puts HealthCare Global Enterprises in the upper half of its industry. The industry median EBITDA Margin % is 10.21. HealthCare Global Enterprises' value of 16.42% is 60.8% above this benchmark. Historically, HealthCare Global Enterprises' own EBITDA Margin % has ranged from 4.07 to 24.06 over the past decade. While the company's 10-year median is 17.11 vs. the industry median of 10.21, HealthCare Global Enterprises has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HealthCare Global Enterprises's current EBITDA Margin % of 16.42% is 60.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on HealthCare Global Enterprises and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HealthCare Global Enterprises's current EBITDA Margin % is 16.42%, which is near median its own 10-year median of 17.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HealthCare Global Enterprises stock overvalued right now?
Based on GuruFocus' analysis, HealthCare Global Enterprises (NSE:HCG) is currently considered Fairly Valued. The stock's GF Value™ is ₹576.14, compared to a current price of ₹600.40 — trading 4.2% above its estimated fair value. The current EBITDA Margin % is 16.42%, which is near median its 10-year median of 17.11 and 60.8% above the Healthcare Providers & Services industry median of 10.21. HealthCare Global Enterprises' overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For HealthCare Global Enterprises (NSE:HCG), the current EBITDA Margin % is 16.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HealthCare Global Enterprises (NSE:HCG) Overvalued in 2026?
Based on GuruFocus' analysis, HealthCare Global Enterprises stock appears to be overvalued.
The current stock price of ₹600.40 is trading 4.2% above its estimated GF Value™ of ₹576.14.
GuruFocus considers HealthCare Global Enterprises to be Fairly Valued.
Key valuation signals for NSE:HCG:
EBITDA Margin %: 16.42% (near median its 10-year median of 17.11)
GF Value™: ₹576.14 vs. price of ₹600.40 (4.2% above fair value)
Industry Position: 60.8% above the Healthcare Providers & Services median (#207 of 668)
No single metric tells the full story. See the NSE:HCG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HealthCare Global Enterprises Business Description
HealthCare Global Enterprises Ltd operates in oncology, providing comprehensive cancer diagnosis and treatment services including medical oncology, radiation therapy, and surgical oncology. It also offers fertility treatment services under the Milann brand, along with multi-specialty hospital care in key medical disciplines. The company's operations span many metropolitan and non-metro cities across India and extend internationally with cancer care centers in Africa. HCG generates revenue through patient services in oncology, fertility treatments, diagnostics, and multi-specialty hospital care, leveraging technology and a networked business model to deliver patient-centric healthcare.
79GF Score
Get the complete analysis for NSE:HCG
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:HCG has been successfully added to your 
